Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
The company reported earnings of 14 cents per share in the year-ago quarter. Revenues increased 31% year over year to $135.4 million. The figure beat the Zacks Consensus Estimate of $130 million. The top line solely comprises product sales of Cushing's syndrome drug, Korlym. Corcept Therapeutics Incorporated Price, Consensus and EPS Surprise Corcept Therapeutics Incorporated price-consensus-eps-surprise-chart | Corcept Therapeutics Incorporated Quote Quarter in Detail Revenues from Korlym met our model estimate of $135.4 million. Research and development expenses surged 48.8% year over year to $54.7 million. Selling, general and administrative expenses increased around 11.4% year over year to $47.1 million. Consequently, operating expenses increased to $103.7 million, up 28.8% from the quarter-ago quarter's level. Corcept's shares lost 20% in the past six months against the industry growth of 4.3%. Image Source: Zacks Investment Research Cash and investments as o
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallGlobeNewswire
- Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
CORT
Earnings
- 2/15/24 - Beat
CORT
Analyst Actions
- 4/23/24 - HC Wainwright
CORT
Sec Filings
- 4/18/24 - Form DEFA14A
- 4/17/24 - Form ARS
- 4/17/24 - Form 8-K
- CORT's page on the SEC website